domingo, 30 de julio de 2023

Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study

https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(23)00103-5/fulltext?dgcid=hubspot_email_covidalerts&utm_campaign=covidalerts&utm_medium=email&_hsmi=268172138&_hsenc=p2ANqtz-_sJxpFSxQ7Hgg7NckRH8O4N8NIfg7_94DACl7lPv1W8-mcyv7RnBk_azyGCQOcZeu7HmwZ6_3pQXexWyCjK0MRLNmjwA&utm_content=268146206&utm_source=hs_email

No hay comentarios:

Publicar un comentario